Cue Biopharma Presents Updated Data From Phase 1 Trial of CUE-101 In Recurrent/Metastatic HPV+ Head And Neck Cancer At ASCO 2024
Portfolio Pulse from Benzinga Newsdesk
Cue Biopharma presented updated data from its Phase 1 trial of CUE-101 in recurrent/metastatic HPV+ head and neck cancer at ASCO 2024. The trial showed a 46% overall response rate and a 12-month overall survival rate of 96% in first-line treatment with CUE-101 and KEYTRUDA. Median overall survival in second-line treatment with CUE-101 monotherapy was 20.8 months, significantly higher than historical data.
June 04, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cue Biopharma presented promising Phase 1 trial results for CUE-101 in HPV+ head and neck cancer, showing high response and survival rates. This could positively impact the stock price in the short term.
The positive trial results for CUE-101, including high overall response and survival rates, are likely to boost investor confidence and positively impact Cue Biopharma's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100